Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
CRISPR Gene Editing: Beam Therapeutics
04:36am, Thursday, 30'th Nov 2023
Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to correct a wide r
The 3 Best Gene Editing Stocks on the Frontier of Medicine
05:43pm, Monday, 20'th Nov 2023
Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics�
Is Beam Therapeutics Stock a Buy Now?
07:15am, Saturday, 18'th Nov 2023
Beam Therapeutics has what it needs to try to deliver its next clinical milestones. It's still running years behind other biotechs with its lead program.
3 Monster Stocks in the Making
06:49am, Saturday, 18'th Nov 2023
Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare ge
What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock
01:32pm, Friday, 17'th Nov 2023
Beam Therapeutics Inc. (BEAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
05:50am, Tuesday, 14'th Nov 2023
Twilio could be poised to use AI to disrupt customer communications. Beam Therapeutics is a pioneer in developing therapies using a highly precise method of gene editing.
Beam Therapeutics: Sale Of Rights To Verve's In-Vivo Candidates An Odd Decision
04:50pm, Friday, 10'th Nov 2023
Beam Therapeutics Inc.'s valuation has declined, as its progress in identifying candidates to work with its base editing technology and moving them into the clinic has been slow. Beam's lead program f
Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect?
11:16am, Friday, 10'th Nov 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 139.8% in Beam Therapeutics Inc. (BEAM). While the effectiveness of this highly sought-after metric is question
Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates
02:17pm, Thursday, 09'th Nov 2023
Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now
08:30am, Sunday, 05'th Nov 2023
Biotech stocks have been under extreme pressure over the prior 24 months. This industry-wide move lower may have created a handful of once-in-a-lifetime opportunities for investors.
Inside Cathie Wood's Portfolio: 3 Stocks She Is Betting Millions On
05:40am, Wednesday, 01'st Nov 2023
Cathie Wood, the brilliant mind behind ARK Invest, is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have made waves in the financial world, and millions o
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
10:00am, Tuesday, 31'st Oct 2023
Beam Therapeutics is refocusing its pipeline and shedding a lot of staff. This should allow the early-stage biotech to stretch its cash a bit further.
Beam Therapeutics up 10% on $600m Lilly deal
08:37am, Tuesday, 31'st Oct 2023
Shares in Beam Therapeutics Inc were up 10% premarket following a deal to sell rights to a licensing deal with Verve Therapeutics to Eli Lilly and Co (NYSE:LLY). An upfront $250 million cash and pap
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:17am, Monday, 30'th Oct 2023
Beam Therapeutics Inc. (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Reasons Beam Therapeutics Remains a Risky Stock
09:18am, Monday, 30'th Oct 2023
Beam recently announced a reorganization that involves layoffs and a narrowing of its pipeline. The company lost $82.8 million in the second quarter.
